Cannabis Investment Report Highlights FDA Approval Prospects and Price Trends

Cannabis Investment Report Highlights FDA Approval Prospects and Price Trends The passage provides market data and regulatory updates on cannabis-derived pharmaceuticals and price trends, but lacks specific allegations, financial flows, or connections to high‑profile officials. It offers limited investigative value beyond general industry insight. Key insights: FDA may approve the first cannabis‑derived drug (Epidiolex) in 2018.; GW Pharmaceuticals submitted an NDA for Epidiolex in October 2017.; Sativex is approved in the UK and other countries but not in the US.